EGFR and non-small cell lung carcinoma: EGFR target therapy prescription is limited to advanced stages of NSCLC; therefore, all the patients included in the liquid biopsy analyses had either progressed or already had a stage IIIA–IV disease; clinical characteristics are reported in Table 1.